Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi

Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Gabriele Buda, A. L. Molinari, Luca Baldini, D. Vallisa, Marina Cesaretti, Pellegrino Musto, Sonia Ronconi, Giorgina Specchia, Franco Silvestris, L. Guardigni, Angela Ferrari, Annalisa Chiapella, Angelo Michele Carella, Armando Santoro, Francesco Di Raimondo, Luigi Marcheselli, Sacchi Samantha Pozzi

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e196-e199
JournalHaematologica
Volume101
Issue number5
DOIs
Publication statusPublished - Apr 30 2016

Keywords

  • Efficacy
  • Indolent
  • Lenalidomide
  • Non-follicular lymphoma
  • Recurrent
  • Rituximab
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this

Sacchi, S., Marcheselli, R., Bari, A., Buda, G., Molinari, A. L., Baldini, L., Vallisa, D., Cesaretti, M., Musto, P., Ronconi, S., Specchia, G., Silvestris, F., Guardigni, L., Ferrari, A., Chiapella, A., Carella, A. M., Santoro, A., Di Raimondo, F., Marcheselli, L., & Pozzi, S. S. (2016). Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 101(5), e196-e199. https://doi.org/10.3324/haematol.2015.139329